Romano Brothers AND Company Sells 6,801 Shares of Bristol-Myers Squibb (NYSE:BMY)

Romano Brothers AND Company lowered its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 8.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 74,348 shares of the biopharmaceutical company’s stock after selling 6,801 shares during the period. Romano Brothers AND Company’s holdings in Bristol-Myers Squibb were worth $4,205,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Seven Eight Capital LP bought a new position in shares of Bristol-Myers Squibb during the second quarter worth about $392,000. Benjamin F. Edwards & Company Inc. increased its position in Bristol-Myers Squibb by 6.0% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 94,911 shares of the biopharmaceutical company’s stock valued at $3,941,000 after purchasing an additional 5,382 shares during the period. Bridges Investment Management Inc. raised its holdings in Bristol-Myers Squibb by 15.6% during the 2nd quarter. Bridges Investment Management Inc. now owns 14,600 shares of the biopharmaceutical company’s stock worth $606,000 after purchasing an additional 1,971 shares during the last quarter. AE Wealth Management LLC lifted its position in shares of Bristol-Myers Squibb by 17.2% in the 2nd quarter. AE Wealth Management LLC now owns 108,803 shares of the biopharmaceutical company’s stock worth $4,519,000 after purchasing an additional 15,934 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 55,336 shares of the biopharmaceutical company’s stock valued at $2,298,000 after purchasing an additional 338 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the transaction, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Samit Hirawat bought 1,830 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were acquired at an average cost of $54.67 per share, with a total value of $100,046.10. Following the completion of the transaction, the executive vice president now owns 62,109 shares in the company, valued at approximately $3,395,499.03. The trade was a 3.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.09% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. UBS Group boosted their target price on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, October 9th. Leerink Partnrs raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. Jefferies Financial Group raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and raised their target price for the stock from $63.00 to $70.00 in a research note on Monday, December 16th. Daiwa Capital Markets raised Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research note on Wednesday, November 13th. Finally, Barclays raised their price objective on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a research report on Monday, October 7th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb has a consensus rating of “Hold” and an average price target of $56.27.

Bristol-Myers Squibb Trading Down 0.0 %

BMY stock opened at $56.35 on Friday. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The business has a 50-day simple moving average of $57.53 and a two-hundred day simple moving average of $51.92. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $61.08.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.31. The company had revenue of $11.89 billion for the quarter, compared to analysts’ expectations of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. Bristol-Myers Squibb’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.00 earnings per share. Equities analysts forecast that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be issued a $0.62 dividend. The ex-dividend date of this dividend is Friday, January 3rd. This represents a $2.48 annualized dividend and a dividend yield of 4.40%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio is currently -69.08%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.